Navigation Links
Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkin's Lymphoma
Date:10/15/2008

Zevalin(R) First-Line Indolent (FIT) Phase III Clinical Trial results

published in Journal of Clinical Oncology

SEATTLE, Oct. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Journal of Clinical Oncology has published the results of the First-line Indolent Trial (FIT) demonstrating that use of Zevalin(R)([90Y]-ibritumomab tiuxetan) in consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma provided important patient benefits including a significant improvement in progression free survival. A companion editorial discussed the growing evidence for the efficacy of radioimmunotherapy (RIT) in B-cell lymphomas. Cell Therapeutics has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for use of Zevalin in first-line consolidation therapy based on the FIT data.

Oliver W. Press, M.D., Ph.D., Member of the Fred Hutchinson Cancer Research Center and Professor at the University of Washington, commented in his editorial that the studies "confirm and extend prior data demonstrating the tremendous potential of RIT in the treatment of B-cell NHL at diagnosis and after relapse at both conventional and myeloablative doses. Despite the overwhelming body of evidence, however, RIT remains underused in the United States and other countries. The reasons for this underuse have been widely debated but seem to be related, at least partially, to logistic issues involved in the transfer of care from the hematologist/oncologist to the nuclear medicine physician, concerns about inadequate reimbursement by Medicare for RIT, and exaggerated emphasis on delayed effects such as marrow damage and secondary malignancies. It is hoped that studies such as those in this issue would encourage wider appreciation and use of RIT."

"We couldn't agree more with Dr. Press' comments about
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing
2. Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years
3. Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT
4. Landmark HIV/AIDS Publication Launches at International AIDS Society Conference in Mexico City
5. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
6. TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial
7. Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
8. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
9. Hospital Launches Landmark Emergency Medicine Project
10. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
11. Viatronix V3D-Colon Utilized in Another Landmark Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... NEWPORT BEACH, Calif. , Sept. 30, 2014 ... prestigious accreditation of the American Association of Tissue ... Russell Cook , Chief Executive Officer. ... on-site inspection by a specially trained AATB inspector.  ... and administrative performance within the facility meets or ...
(Date:9/30/2014)... -- Georgia-Pacific Professional is a leading provider of hygienic ... range of away from home applications. Building on ... including hospitals, long-term care facilities, surgical centers and ... products and solutions to the dental community. ... control in the dental office," said Sean ...
(Date:9/30/2014)... , Sept. 30, 2014 Passport Health, ... America , has launched FluFree.com, a website designed ... vaccinations. For 20 years, Passport Health has ... the flu. The launch of FluFree.com is designed to ... and the number of people who actually chose to ...
Breaking Medicine Technology:Biostructures, LLC Earns AATB Accreditation 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 2Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 3
... CAMBRIDGE, Mass. Dec. 10 The US Army, through the ... Technologies a contract to develop a robotic approach to airway ... clearing a patient,s airway and inserting a tube to maintain ... intubation, is critical as the loss of proper air circulation ...
... , TITUSVILLE, N.J., Dec. 10 Treatment with once-monthly ... CONSTA®, according to new data from a comparative study of ... clinical trial were released this week. , An estimated one ... brain disorder that impairs a person,s ability to think clearly, ...
Cached Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10
(Date:9/30/2014)... unusual character from a "Seinfeld" episode or a John ... called SCID, short for severe combined immunodeficiency, forces patients ... their bodies, natural defenses are too weak to fight ... new births each year worldwide, SCID is a cousin ... immunodeficiency virus HIV/AIDS. , Now, using a mouse ...
(Date:9/30/2014)... Researchers report that some stickleback fish fathers can have ... most attentive fish dads cause their offspring to behave ... predators. These behavioral changes are accompanied by changes in ... appear in the Proceedings of the Royal ... of evidence that moms are very important for their ...
(Date:9/30/2014)... a very valuable procedure by which to screen ... seems that healthy Americans who do undergo this ... before they actually should. Gina Kruse of ... advise that endoscopists stick to the national guidelines ... Journal of General Internal Medicine , published by ...
(Date:9/30/2014)... Carolina (PRWEB) September 30, 2014 ... and IT Infrastructure analytics across data center, cloud ... has achieved an important milestone of helping more ... plan for important projects such as IT infrastructure ... , The strong customer engagement rates and ...
(Date:9/30/2014)... September 30, 2014 A market research ... intelligence agency states that the global medical imaging reagents ... 18.5 billion by the end of 2019. The worldwide ... 10.3 billion in 2012, will report a compounded annual ... 18.5 billion worth market by 2019. , Browse the ...
Breaking Medicine News(10 mins):Health News:Virginia Tech researchers discover potential biomarker to detect 'bubble boy' disorder 2Health News:Virginia Tech researchers discover potential biomarker to detect 'bubble boy' disorder 3Health News:In stickleback fish, dads influence offspring behavior and gene expression 2Health News:In stickleback fish, dads influence offspring behavior and gene expression 3Health News:Americans undergo colonoscopies too often, study finds 2Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 2Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 3Health News:Global Medical Imaging Reagents Market Segment up to 2019: Transparency Market Research 2Health News:Global Medical Imaging Reagents Market Segment up to 2019: Transparency Market Research 3
... ... provide alternative natural relief prior to considering drugs. , ... St. Louis, MO (PRWEB) December 17, 2009 -- ... and flaking associated with severe skin conditions . Developed by Astrel Genome ...
... ... measures and outcomes reporting to monitor the impact of expected health improvements as it ... the contract. , ... Jacksonville, FL (PRWEB) December 17, 2009 -- HealthScreen Disease Management, an independent ...
... ... tub company helps raise money for kids battling severe illness and acute injury ... Salt Lake City, ... donation of a Bullfrog Spa to aid in fund raising efforts for Primary Children’s ...
... AUSTIN, Texas, Dec. 16 Austin,s Custom Tops , a ... Gray and Hill Country Home Health, a slider-eating throwdown at the ... up to cheer on the two brave contestants who ate their ... The Austin Children,s Shelter. , What started as a casual ...
... , CHEVY CHASE, Md., Dec. 16 ... capital firm, today announced that one of its portfolio ... to be acquired by Ethicon, Inc., a Johnson & ... million (net of estimated cash on hand at time ...
... Immucor, Inc. (Nasdaq: BLUD ), a global leader ... today announced that Paul D. Mintz, M.D. has been appointed ... 1, 2010. , Dr. Mintz has been involved in ... He is a tenured Professor of Pathology and Medicine at ...
Cached Medicine News:Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 2Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 3Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 4Health News:Baptist Health System Selects HealthScreen Disease Management for Employee Health Management Services 2Health News:Bullfrog Spas Helps Critically Ill Children 2Health News:Bullfrog Spas Helps Critically Ill Children 3Health News:Bullfrog Spas Helps Critically Ill Children 4Health News:Austin-Based Business Co-Sponsors Gastric Feat for Charity 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:Immucor Appoints New Board Director 2
Cannulated Interference Screws...
... Endoscopy Components, LLC offers ... Equipment "Made in Germany". ... manufactured according to ISO ... most excellent design elements ...
... moisturizing mist for the eyes developed with ... from Oregon Health Sciences University's Casey Eye ... (2000) and dry eye patients showed, on ... volume of the eyes' tear film without ...
... array with 275 channels gives ... just 2.2 cm. This ... when using advanced analysis techniques, ... (SAM) or minimum norm methods. ...
Medicine Products: